Psoriasis Clinical Trial
Official title:
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
The purpose of this study is 1) to determine whether Imiquimod or Steroid pretreatment modifies UVB laser light response resulting in increased cell death compared to UVB laser light alone; 2) to determine if pretreatment of psoriatic lesions with Imiquimod or Steroid prior to UVB laser light exposure selectively effects various T cell functions; 3) to determine clinical results from the Imiquimod/Steroid/UVB laser light and correlate those changes with immuno-histochemical changes in the skin; and 4) to determine if single high dose lesion limited UVB laser light intervention combined with Imiquimod or Steroid influences T cell changes
The characteristic lesion of psoriasis is a sharply demarcated erythematous papule or plaque
with excessive scaling due to hyperproliferating keratinocytes, infiltrating granulocytes,
and a dense mononuclear infiltrate with activated T cells. To date, no one mechanism has
been explanatory for the panoply of changes that occur in both the dermis and epidermis of
psoriasis patients. Several key findings have shown that cutaneous T cells play a key role
in the propagation of the disease; memory-type T cells home to the skin, specifically due to
expression of cutaneous lymphocyte antigen (CLA), and are the main effector cells in
psoriatic tissue responsible for the production of cytokines that result in exacerbated
cutaneous inflammation. T cell recruitment is thought to occur in psoriasis, in part, as a
result of cytokine and chemokine release from keratinocytes, macrophages, and endothelial
cells. CLA-positive T cells migrate into the tissues where memory-effector T cells are
activated and expand. This migration is critical to maintenance of the psoriasis lesions,
because anti-LFA-1 antibodies (efalizumab) are effective in treating psoriasis, resulting in
blood lymphocytosis and tissue depletion of T cells. Despite many years of using UVB
phototherapy in the treatment of psoriasis, its mechanism of action is based mainly on in
vitro exposures of isolated cells and on extrapolations from UV effects on normal skin, with
little direct data from lesional skin.
Previously, our studies determined optimal single efficacious dose using the Excimer laser,
refined the mechanism of UVB action in psoriasis, developed key cytokine quantitative meth
-ods to assess targeted mRNA levels in psoriatic tissue after treatment, demonstrated that
regulatory T cells from psoriasis tissue and blood appear to have a functional defect, and
demonstrated that UVA component of solar radiation is a critical and significant contributor
to UV-induced in vivo immuno-suppression. All of these previous findings lead us to our
current hypothesis that direct selective apoptotic effects on the T mem/Teff cells may
result in decreased APC activation and IL-12 over-riding of Treg suppression and a
re-balanced Tre:Tmem/eff cell ratio which in turn may have a sustained remittive effect
(high duration multi-month clearing of a psoriasis lesion after a single UVB laser light
treatment.)
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |